My overall research goal is to assess the clinical validly of specific immune cell subsets identified in our previous studies as novel cellular targets of cancer immunotherapy, develop and/or test immunotherapies that selectively target these cells and rationally combine these therapies with existing treatment options for optimal efficacy while eliciting minimal toxicity. This is the focal point of my research program, aimed at devising and testing novel immunotherapeutic strategies through mechanism-guided approaches. My lab thus strives to translate promising preclinical findings into meaningful therapies and further test their validity in early clinical trials by closely working with established collaborators and by building new clinical connections.